OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	207
Strategies for targeting RNA with small molecule drugs	165
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	120
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	96
Advances in the discovery of drugs that treat pulmonary arterial hypertension	76
Advances in ion channel high throughput screening: where are we in 2023?	62
γ-Secretase: once and future drug target for Alzheimer’s disease	60
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	55
The root cause: why do so many drugs fail to translate from bench to bedside?	49
What is the plausibility that all drugs will be designed by computers by the end of the decade?	48
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	47
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	42
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder	40
Tools and techniques for the discovery of therapeutic aptamers: recent advances	39
Methods in marine natural product drug discovery: what’s new?	39
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	39
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	39
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	38
An update on knowledge graphs and their current and potential applications in drug discovery	37
The rules often neglected in current medicinal chemistry	37
Water in drug design: pitfalls and good practices	37
The potential of microfluidic platforms for neuron differentiation and pain modeling in novel drug discovery	36
Phenotypic screening for new heart failure therapeutics: scalable animal modeling in zebrafish	36
A cautionary tale of paradox and false positives in cannabidiol research	35
Novel insights into structure–activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration	35

Molecular hybridization: a powerful tool for multitarget drug discovery	34
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	34
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	33
The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery	33
Virtual screening: hope, hype, and the fine line in between	32
Current challenges and future perspectives of drug discovery in China	32
Correction	31
Novel hydrogels: are they poised to transform 3D cell-based assay systems in early drug discovery?	31